Microbiotix, Inc.

US Government As Represented by the Secretary of the Army

Albert Einstein College of Medicine

Debra M Mills

John D Williams

Arnab Basu

Norton P Peet

Terry L Bowlin

Bing Li

Kartik Chandran

John M Dye

Donald T Moir

Zachary D Aron

Jay P Barbor

Kelly N Lively

Peter J Nash

The present invention is related to the development of therapeutics and prophylactics for the treatment and/or prevention of filovirus infection in humans and other mammals. A new class of small molecules is disclosed that inhibits the interaction of naturally processed (i.e., proteolytically cleaved) filovirus glycoprotein (GP) with its host receptor Niemann-Pick C1 (NPC1) protein and thus block infection of host cells by filoviruses. Also disclosed are methods of using the small molecule inhibitors in the treatment/prevention of filovirus infection.

Broad spectrum inhibitors of filoviruses

The present invention is related to the development of compounds and methods for inhibiting viral infection in a mammal. A pseudotype virus was developed for use in a high throughput assay for identifying nonpeptidic small molecule inhibitors that prevent viral entry into a host cell.

Inhibitors of viral entry into mammalian cells

Organic compounds showing the ability to inhibit viral glycoprotein (GP)-mediated entry of a filovirus into a host cell are disclosed. The disclosed filovirus entry inhibitor compounds are useful for treating, preventing, or reducing the spread of infections by filovirus including the type species Marburg virus (MARV) and Ebola virus (EBOV). Preferred inhibitors of the invention provide therapeutic agents for combating the Ivory Coast, Sudan, Zaire, Bundibugyo, and Reston Ebola virus strains.

Inhibitors of filovirus entry into host cells

Growing community of inventors

Ayer, MA, United States of America

Debra M Mills